About OrthoTrophix

OrthoTrophix is focused on the development and commercialization of revolutionary therapies that offer new solutions to the unmet medical needs of patients suffering from diseases and conditions involving hard tissues. OrthoTrophix believes that its product candidates have distinct advantages over existing therapies.

The Company’s most advanced project is TPX-100, a candidate first-in-class disease modifying osteoarthritis drug (DMOAD). OrthoTrophix has successfully demonstrated safety and clinical efficacy of TPX-100 in a Phase 2 placebo-controlled study in subjects with knee osteoarthritis in fifteen centers across the U.S. Other joint degenerative conditions such as post-traumatic arthritis and rheumatoid arthritis are potential additional target indications for TPX-100.

OrthoTrophix is a private company operating in the San Francisco Bay Area, incorporated by its three founders in May 2011. OrthoTrophix has raised over $30 million in partnering revenues and equity financing since inception.